European guidelines on upper tract urothelial carcinomas: 2013 update

Morgan Rouprêt, Marko Babjuk, Eva Compérat, Richard Zigeuner, Richard Sylvester, Max Burger, Nigel Cowan, Andreas Böhle, Bas W.G. Van Rhijn, Eero Kaasinen, Joan Palou, Shahrokh F. Shariat

Research output: Contribution to journalArticleResearchpeer-review

333 Citations (Scopus)

Abstract

Context: The European Association of Urology (EAU) guideline group for upper tract urothelial carcinoma (UTUC) has prepared updated guidelines to aid clinicians in assessing the current evidence-based management of UTUC and to incorporate present recommendations into daily clinical practice. Objective: To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians in their daily clinical practice. Evidence acquisition: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified using a systematic search of Medline. Data on urothelial malignancies and UTUCs in the literature were searched using Medline with the following keywords: urinary tract cancer; urothelial carcinomas; upper urinary tract, carcinoma; renal pelvis; ureter; bladder cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; nomogram; and survival. References were weighted by a panel of experts. Evidence synthesis: There is a lack of data in the current literature to provide strong recommendations (ie, grade A) due to the rarity of the disease. A number of recent multicentre studies are now available, and there is a growing interest in UTUC in the recent literature. Overall, 135 references have been included here, but most of these studies are still retrospective analyses. The TNM 2009 classification is recommended. Recommendations are given for diagnosis as well as radical and conservative treatment (ie, imperative and elective cases); additionally, prognostic factors are discussed. Recommendations are also provided for patient follow-up after different therapeutic options. Conclusions: These guidelines contain information for the management of individual patients according to a current standardised approach. Physicians must take into account the specific clinical characteristics of each individual patient when determining the optimal treatment regimen including tumour location, grade, and stage; renal function; molecular marker status; and medical comorbidities. © 2013 European Association of Urology.
Original languageEnglish
Pages (from-to)1059-1071
JournalEuropean Urology
Volume63
Issue number6
DOIs
Publication statusPublished - 1 Jun 2013

Keywords

  • Cytology
  • Guidelines
  • Radical nephroureterectomy
  • Recurrence
  • Renal pelvis
  • Risk factors
  • Survival
  • Ureter
  • Ureteroscopy
  • Urinary tract cancer
  • Urothelial carcinoma

Fingerprint Dive into the research topics of 'European guidelines on upper tract urothelial carcinomas: 2013 update'. Together they form a unique fingerprint.

  • Cite this

    Rouprêt, M., Babjuk, M., Compérat, E., Zigeuner, R., Sylvester, R., Burger, M., Cowan, N., Böhle, A., Van Rhijn, B. W. G., Kaasinen, E., Palou, J., & Shariat, S. F. (2013). European guidelines on upper tract urothelial carcinomas: 2013 update. European Urology, 63(6), 1059-1071. https://doi.org/10.1016/j.eururo.2013.03.032